REVIEW PAPER
Patient safety and efficacy in using antiretroviral drugs in pregnant women: a systematic review
1
School of Pharmacy, Institut Teknologi Bandung, Bandung, Indonesia
2
Department of Pharmacy, Faculty of Health Sciences, University of Muhammadiyah Malang, Malang, Indonesia
3
Faculty of Medicine, University of Muhammadiyah Malang, Malang, Indonesia
These authors had equal contribution to this work
Submission date: 2023-06-01
Final revision date: 2023-10-10
Acceptance date: 2023-10-22
Online publication date: 2026-01-05
KEYWORDS
TOPICS
ABSTRACT
Human immunodeficiency virus (HIV) attacks human immune system by destroying CD4+ T cells, which are the main component of immune system, lowering body's resistance, so that HIV-infected patients are susceptible to other infections. HIV mainly attacks the productive age group, where half of new infection cases occur in people aged under 25.5 years. HIV affects not only an individual's health, but also households, communities, and development and economic growth of any country.
The aim of the study was to investigate the safety of antiretroviral (ARV) regimen use in pregnant women. For that, a systematic review was conducted in literature related to a pre-determined theme. The literature was searched systematically using PRISMA guidelines, and the published articles were search in PubMed, ScienceDirect, and Google Scholar electronic databases. After reading, 13 articles on interventions among pregnant women, neonates, and ARV drug usage were selected. Dolutegravir-based ARV therapy is safe and recommended for pregnant and lactating women. Most of the treatments consists of three ARV drugs, as recommended.
REFERENCES (28)
1.
Rahima P, Irawan E, Fauzia P. Intervensi pada Pasien Dengan Penyakit HIV/AIDS. J Keperawatan BSI 2019; 7: 127-141.
2.
Kovacs L, Kress TC, Belin de Chantemèle EJ. HIV, combination antiretroviral therapy, and vascular diseases in men and women. JACC Basic to Transl Sci 2022; 7: 410-421.
3.
Kumar S, Chauhan RP, Abdel-Aty AH, Alharthi MR. A study on transmission dynamics of HIV/AIDS model through fractional operators. Results Phys 2021; 22: 103855. DOI: https://doi.org/10.1016/j.rinp....
4.
Adelekan M. A critical review of the effectiveness of educational interventions applied in HIV/AIDS prevention. Patient Educ Couns 2017; 100: S11-S16. DOI: http://dx.doi.org/10.1016/j.pe....
5.
Salman SM. Memory and media coverage effect on an HIV/AIDS epidemic model with treatment. J Comput Appl Math 2021; 385: 113203. DOI: https://doi.org/10.1016/j.cam.....
6.
Anthamatten A. Prescribing contraindications and cautions for HIV. J Nurse Pract 2022; 18: 45-48.
7.
Ahmed A, Dujaili JA, Hashmi FK, Awaisu A, Chaiyakunapruk N, Hasan SS. The economic impact of pharmacist care for people living with HIV/AIDS: a systematic review. Explor Res Clin Soc Pharm 2021; 3: 100066. DOI: https://doi.org/10.1016/j.rcso....
8.
Zash R, Jacobson DL, Diseko M, Mayondi G, Mmalane M, Essex M, et al. Comparative safety of antiretroviral treatment regimens in pregnancy. JAMA Pediatr 2017; 171: e172222. DOI: 10.1001/jamapediatrics.2017.2222.
9.
Kala S, Watson B, Zhang JG, Papp E, Guzman Lenis M, Dennehy M, et al. Improving the clinical relevance of a mouse pregnancy model of antiretroviral toxicity; a pharmacokinetic dosing-optimization study of current HIV antiretroviral regimens. Antiviral Res 2018; 159: 45-54.
10.
Ejigu Y, Magnus JH, Sundby J, Magnus MC. Pregnancy outcome among HIV-infected women on different antiretroviral therapies in Ethiopia: a cohort study. BMJ Open 2019; 9: e027344. DOI: 10.1136/bmjopen-2018-027344.
11.
Maswabi K, Ajibola G, Bennett K, Capparelli EV, Jean-Philippe P, Moyo S, et al. Safety and efficacy of starting antiretroviral therapy in the first week of life. Clin Infect Dis 2021; 72: 388-393.
12.
Updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring [Internet]. Geneva: World Health Organization; 2021.
13.
Karyadi T. Keberhasilan Pengobatan Antiretroviral (ARV). J Penyakit Dalam Indones 2017; 4: 2-4.
15.
Kanters S, Vitoria M, Zoratti M, Doherty M, Penazzato M, Rangaraj A, et al. Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: a systematic literature review and network meta-analysis. EClinicalMedicine 2020; 28: 100573. DOI: https://doi.org/10.1016/j.ecli....
16.
Hill A, Clayden P, Thorne C, Christie R, Zash R. Safety and pharmacokinetics of dolutegravir in HIV-positive pregnant women: a systematic review. J Virus Erad 2018; 4: 66-71.
17.
Yuniar CT, Pratiwi B, Ihsan AF, Laksono BT, Risfayanti I, Fatha-dina A, et al. Adverse events reporting quality of randomized controlled trials of COVID-19 vaccine using the CONSORT criteria for reporting harms: a systematic review. Vaccines (Basel) 2022; 10: 313. DOI: 10.3390/vaccines10020313.
18.
Shukralla AA, Tudur-Smith C, Powell GA, Williamson PR, Mar-son AG. Reporting of adverse events in randomised controlled trials of antiepileptic drugs using the CONSORT criteria for reporting harms. Epilepsy Res 2011; 97: 20-29.
19.
Santini-Oliveira M, De Cássia Elias R, Veloso VG, Cattani VB, Yanavich C, Velasque L, et al. Randomized clinical trial comparing the pharmacokinetics of standard- and increased-dosage lopinavir-ritonavir coformulation tablets in HIV-positive pregnant women. Antimicrob Agents Chemother 2014; 58: 2884-2893.
20.
Natureeba P, Ades V, Luwedde F, Mwesigwa J, Plenty A, Okong P, et al. Lopinavir/ritonavir-based antiretroviral treatment (ART) versus efavirenz-based ART for the prevention of malaria among HIV-infected pregnant women. J Infect Dis 2014; 210: 1938-1945.
21.
Ochanda PN, Lamorde M, Kintu K, Wang D, Chen T, Malaba T, et al. A randomized comparison of health-related quality of life outcomes of dolutegravir versus efavirenz-based antiretroviral treatment initiated in the third trimester of pregnancy. AIDS Res Ther 2022; 19: 24. DOI: 10.1186/s12981-022-00446-3.
22.
Lockman S, Brummel SS, Ziemba L, Stranix-Chibanda L, Coletti A, Philippe PJ, et al. Efficacy and safety of dolutegravir-and tenofovir alafenamide fumarate-containing HIV antiretroviral treatment regimens started in pregnancy: a randomised controlled trial. HHS Public Access 2021; 176: 139-148.
23.
Malaba TR, Nakatudde I, Kintu K, Colbers A, Chen T, Reynolds H, et al. 72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study. Lancet HIV 2022; 9: e534-e543. DOI: 10.1016/S2352-3018(22)00173-4.
24.
Bollen P, Freriksen J, Konopnicki D, Weizsäcker K, Hidalgo Tenorio C, Moltó J, et al. The effect of pregnancy on the pharmacokinetics of total and unbound dolutegravir and its main metabolite in women living with human immunodeficiency virus. Clin Infect Dis 2021; 72: 121-127.
25.
Meireles MV, Pascom ARP, Duarte EC, McFarland W. Comparative effectiveness of first-line antiretroviral therapy: results from a large real-world cohort after the implementation of dolutegravir. AIDS 2019; 33: 1663-1668.
26.
Prins HAB, Zino L, Svensson EM, Verbon A, de Bree GJ, Prins JM, et al. Exposure and virologic outcomes of dolutegravir combined with ritonavir boosted darunavir in treatment-naïve individuals enrolled in the Netherlands Cohort Study on Acute HIV infection (NOVA). Int J Antimicrob Agents 2023; 61: 106697. DOI: 10.1016/j.ijantimicag.2022.106697.
27.
Ebrahim I, Maartens G, Wiesner L, Orrell C, Smythe W, McIlleron H. Pharmacokinetic profile and safety of adjusted doses of darunavir/ritonavir with rifampicin in people living with HIV. J Antimicrob Chemother 2020; 75: 1019-1025.
28.
Mulligan N, Best BM, Wang J, Capparelli EV, Stek A, Barr E, et al. Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV. AIDS 2018; 32: 729-737.
Share
RELATED ARTICLE
| eISSN: | 1732-2707 |
| ISSN: | 1730-1270 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
